HRT Financial’s Axsome Therapeutics AXSM Stock Holding History

HRT Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.93M	Buy	+11,400	New	+$1.97M	﹤0.01%	1647

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's AXSM Position: Q1 2026 in Review

HRT Financial sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 18,862 shares — an estimated $3.26M sold.

HRT Financial first reported a position in AXSM in Q4 2019 and held it in 6 quarters. The position peaked at $4.19M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

HRT Financial reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 18,862 Axsome Therapeutics shares in Q1 2026, an estimated $3.26M.
HRT Financial first reported a position in Axsome Therapeutics in Q4 2019 and held it in 6 quarters.
HRT Financial's Axsome Therapeutics position peaked at $4.19M in Q4 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.